Biomarker Profiles in Serum and CSF for Early Diagnosis of Selected Neurodegenerative Diseases: Serum and CSF for Early Diagnosis of Neurodegenerative Diseases

Muhammad Anique; Masooma Talib; Amna Ihsan; Iqra Anwar; Ambreen Zeeshan; Naveed Ahsan

doi:10.54393/pjhs.v5i09.2153

Authors

Muhammad Anique Department of Pathology, Bhitai Medical and Dental College, Mirpurkhas, Pakistan
Masooma Talib Department of Biochemistry, Watim Medical and Dental College, Rawalpindi, Pakistan
Amna Ihsan Department of Biochemistry, King Edward Medical University, Lahore, Pakistan
Iqra Anwar Department of Biochemistry, Watim Medical and Dental College, Rawalpindi, Pakistan
Ambreen Zeeshan Department of Biochemistry, Fatima Memorial College of Medicine and Dentistry, Lahore, Pakistan
Naveed Ahsan Department of Biochemistry, Bhitai Medical and Dental College, Mirpurkhas, Pakistan

DOI:

https://doi.org/10.54393/pjhs.v5i09.2153

Keywords:

Alzheimer's Disease, Biomarkers, Cerebrospinal Fluid, Neurodegenerative Disorders

Abstract

Biomarker research and justification for neurodegenerative illnesses have seen enormous efforts over the last ten years. Bio-fluid-based biomarkers have been believed to provide a better and easier approach to detecting biomarkers for diagnosing nervous system pathologies. Objectives: To evaluate the diagnostic potential of certain biomarkers in serum and cerebrospinal fluid to diagnose Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease at an initial stage. Methods: 280 participants were taken and distributed into four groups, comprising, 70 patients with early-stage Alzheimer’s disease, 70 with early-stage Parkinson’s disease, 70 with early-stage Huntington’s disease, and 70 age-matched healthy controls. Blood and cerebrospinal fluid samples were drawn and medical history was taken from the patients. Serum and cerebrospinal fluid levels of amyloid-beta (Aβ42), total tau (t-tau), phosphorylated tau (p-tau), alpha-synuclein, huntingtin protein, and neuro-filament light chain were evaluated using enzyme-linked immunosorbent assays. Results: Alzheimer’s disease patients showed reduced serum Aβ42 (80.4 ± 15.6 pg/mL) and elevated t-tau (140.5 ± 18.2 pg/mL). Parkinson’s disease patients had raised serum alpha-synuclein (12.5 ± 2.3 ng/mL) and neuro-filament light chain. Huntington’s disease patients showed significant increases in serum huntingtin protein (8.2 ± 2.0 ng/mL). These profiles indicate efficacy in early diagnosis. Conclusions: It was concluded that Aβ42 and tau effectively detect Alzheimer’s disease, while Parkinson’s disease patients can be effectively diagnosed with Serum and cerebrospinal fluid levels of the neuro-filament light chain. Similarly, huntingtin protein and neuro-filament light chain are sensitive enough to detect Huntington’s disease at its early stages.

References

Vogt AC, Jennings GT, Mohsen MO, Vogel M, Bachmann MF. Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid Β. International Journal of Molecular Sciences. 2023 Feb; 24(4): 3895. doi: 10.3390/ijms24043895.

Hampel H, Hardy J, Blennow K, Chen C, Perry G, Kim SH et al. The Amyloid-Β Pathway in Alzheimer’s Disease. Molecular Psychiatry. 2021 Oct; 26(10): 5481-503. doi: 10.1038/s41380-021-01249-0.1

Matuszyk MM, Garwood CJ, Ferraiuolo L, Simpson JE, Staniforth RA, Wharton SB. Biological and Methodological Complexities of Beta‐Amyloid Peptide: Implications for Alzheimer’s Disease Research. Journal of Neurochemistry. 2022 Feb; 160(4): 434-53. doi: 10.1111/jnc.15538.

Shah AA, Kashyap K, Gupta A. Parkinson's Disease: An Introduction to the Causes and Management Strategies. International Journal of Pharmaceutical Research (09752366). 2020 Oct; 12(4). doi: 10.31838/ijpr/2020.12.04.698.

Shankar J, Geetha KM, Wilson B. Potential Applications of Nanomedicine for Treating Parkinson's Disease. Journal of Drug Delivery Science and Technology. 2021 Dec; 66: 102793. doi: 10.1016/j.jddst.2021.102793.

Chen JH, Chan L, Chung CC, Bamodu OA, Hong CT. Blood Neurofilament Light Chain in Parkinson’s Disease: Comparability Between Parkinson’s Progression Markers Initiative (Ppmi) And Asian Cohorts. Journal of Clinical Medicine. 2021 Oct; 10(21): 5085. doi: 10.3390/jcm10215085.

Bourn D and Bourn D. Autosomal Dominant Inheritance and Huntington Disease. Diagnostic Genetic Testing: Core Concepts and the Wider Context for Human DNA Analysis. 2022: 23-35. doi: 10.1007/978-3-030-85510-9_2.

Doroszkiewicz J, Groblewska M, Mroczko B. Molecular Biomarkers and Their Implications for the Early Diagnosis of Selected Neurodegenerative Diseases. International Journal of Molecular Sciences. 2022 Apr; 23(9): 4610. doi: 10.3390/ijms23094610.

Klyucherev TO, Olszewski P, Shalimova AA, Chubarev VN, Tarasov VV, Attwood MM et al. Advances in the Development of New Biomarkers for Alzheimer’s Disease. Translational Neurodegeneration. 2022 Apr; 11(1): 25. doi: 10.1186/s40035-022-00296-z.

Koníčková D, Menšíková K, Tučková L, Hényková E, Strnad M, Friedecký D et al. Biomarkers of Neurodegenerative Diseases: Biology, Taxonomy, Clinical Relevance, and Current Research Status. Biomedicines. v2022 Jul; 10(7): 1760. doi: 10.3390/biomedicines10071760.

Varesi A, Carrara A, Pires VG, Floris V, Pierella E, Savioli G et al. Blood-Based Biomarkers for Alzheimer’s Disease Diagnosis and Progression: An Overview. Cells. 2022 Apr; 11(8): 1367. doi: 10.3390/cells11081367.

Ehrenberg AJ, Khatun A, Coomans E, Betts MJ, Capraro F, Thijssen EH et al. Relevance of Biomarkers Across Different Neurodegenerative Diseases. Alzheimer's Research & Therapy. 2020 Dec; 12: 1-1. doi: 10.1186/s13195-020-00637-y.

Hansson O. Biomarkers for Neurodegenerative Diseases. Nature Medicine. 2021 Jun; 27(6): 954-63.

Baldacci F, Mazzucchi S, Della Vecchia A, Giampietri L, Giannini N, Koronyo-Hamaoui M et al. The Path to Biomarker-Based Diagnostic Criteria for the Spectrum of Neurodegenerative Diseases. Expert Review of Molecular Diagnostics. 2020 Apr; 20(4): 421-41. doi: 10.1038/s41591-021-01382-x.

Pathak N, Vimal SK, Tandon I, Agrawal L, Hongyi C, Bhattacharyya S. Neurodegenerative Disorders of Alzheimer, Parkinsonism, Amyotrophic Lateral Sclerosis and Multiple Sclerosis: An Early Diagnostic Approach for Precision Treatment. Metabolic Brain Disease. 2021 Nov; 37: 1-38. doi: 10.1007/s11011-021-00800-w.

Michno W, Blennow K, Zetterberg H, Brinkmalm G. Refining The Amyloid Β Peptide and Oligomer Fingerprint Ambiguities in Alzheimer’s Disease: Mass Spectrometric Molecular Characterization in Brain, Cerebrospinal Fluid, Blood, and Plasma. Journal of Neurochemistry. 2021 Oct; 159(2): 234-57. doi: 10.1111/jnc.15466.

Xu C, Zhao L, Dong C. A Review of Application of Aβ 42/40 Ratio in Diagnosis and Prognosis of Alzheimer’s Disease. Journal of Alzheimer's Disease. 2022 Jan; 90(2): 495-512. doi: 10.3233/JAD-220673.

Moore KB, Hung TJ, Fortin JS. Hyper-phosphorylated tau (p-tau) and Drug Discovery in the Context of Alzheimer's Disease and Related Tauopathies. Drug Discovery Today. 2023 Mar; 28(3): 103487. doi: 10.1016/j.drudis.2023.103487.

Campbell MR, Ashrafzadeh‐Kian S, Petersen RC, Mielke MM, Syrjanen JA, van Harten AC et al. P‐tau/aβ42 and aβ42/40 Ratios in CSF Are Equally Predictive of Amyloid Pet Status. Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring. 2021 May; 13(1): e12190. doi: 10.1002/dad2.12190.

Grangeon L, Paquet C, Guey S, Zarea A, Martinaud O, Rotharmel M et al. Cerebrospinal Fluid Profile of Tau, Phosphorylated Tau, Aβ 42, and Aβ 40 in Probable Cerebral Amyloid Angiopathy. Journal of Alzheimer's Disease. 2022 Jan; 87(2): 791-802. doi: 10.3233/JAD-215208.

Ganguly U, Singh S, Pal S, Prasad S, Agrawal BK, Saini RV et al. Alpha-Synuclein as A Biomarker of Parkinson’s Disease: Good, But Not Good Enough. Frontiers in Aging Neuroscience. 2021 Jul; 13: 702639. doi: 10.3389/fnagi.2021.702639.

Caron NS, Haqqani AS, Sandhu A, Aly AE, Findlay Black H, Bone JN et al. Cerebrospinal Fluid Biomarkers for Assessing Huntington Disease Onset and Severity. Brain Communications. 2022 Dec; 4(6): fcac309. doi: 10.1093/braincomms/fcac309.